Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cresco Labs Inc C.CL

Alternate Symbol(s):  CRLBF

Cresco Labs Inc. is an integrated multi-state cannabis operator in the United States. The Company is licensed to cultivate, manufacture, and sell retail and medical cannabis products primarily through Sunnyside, Cresco Labs’ national dispensary brand, and third-party retail stores. Its family brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal Farms, Remedi and Mindy’s. Its portfolio consists of over 400 products. The Company's products are sold in over 1,600 dispensaries across the country. Its Cresco offers consistent strains, available in a variety of product forms at dispensaries and retail locations nationwide. Its High Supply lab-tested; and available in vape carts, vape pens, flower, popcorn, shake, shorties and concentrates. Its Remedi products provide a consistent and trusted alternative to traditional pharmaceuticals like opioids. Its Mindy’s offers dosed edibles created by James Beard. It is the wholesaler of branded cannabis products.


CSE:CL - Post by User

Post by Nicezyon Mar 25, 2021 9:51am
144 Views
Post# 32874423

CBD's Antioxidant Properties

CBD's Antioxidant Properties
 
So far, we know that CBD is a proven treatment when it comes to epilepsy, and early research is showing promise in regards to various anxiety disorders. In 2018, the first FDA-approved drug, cannabidiol, containing CBD was released on the market to treat two different kinds of epilepsy —  Dravet syndrome and Lennox-Gastaut syndrome.
 
For patients as young as 3 years old, the FDA has authorized the procedure. Check the disclaimer on profile and landing page.
<< Previous
Bullboard Posts
Next >>